Exelixis, Inc.(EXEL)Earnings, Financials & Key Ratios

EXEL•NASDAQ

$44.42

$11.28B mkt cap·16.0× P/E·Price updated May 6, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryOncology Therapeutics Developers

AboutExelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.Show more

Revenue$2.32B+7.0%
EBITDA$901M+42.3%
Net Income$783M+50.1%
EPS (Diluted)2.78+58.0%
Gross Margin96.39%
EBITDA Margin38.84%+33.0%
Operating Margin37.59%+34.8%
Net Margin33.73%+40.3%
ROE35.53%+53.6%
ROIC32.15%+56.3%
Debt/Equity0.08-5.8%

Analysis→Technical→

EXEL Key Insights

Exelixis, Inc. (EXEL) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Company is almost debt free
✓Excellent 3Y average ROE of 22.5%
✓Strong 5Y profit CAGR of 47.6%
✓Strong Piotroski F-Score: 7/9
✓FCF machine: 36.4% free cash flow margin
✓Strong 5Y sales CAGR of 18.6%

✗Weaknesses

No significant weaknesses identified

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

EXEL Price & Volume

Exelixis, Inc. (EXEL) stock price & volume — 10-year historical chart

Loading chart...

EXEL Growth Metrics

Exelixis, Inc. (EXEL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years51.19%

5 Years18.63%

3 Years12.93%

TTM3.33%

Profit CAGR

10 Years-

5 Years47.58%

3 Years62.53%

TTM29.5%

EPS CAGR

10 Years-

5 Years51.35%

3 Years70.59%

TTM37.9%

Return on Capital

10 Years19.33%

5 Years17.37%

3 Years21.74%

Last Year35.01%

EXEL Recent Earnings

Exelixis, Inc. (EXEL) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 9/12 qtrs (75%)●Beat Revenue 7/12 qtrs (58%)

Q1 2026Latest

Feb 10, 2026

EPS

$0.94

Est $0.77

+22.1%

Revenue

$599M

Est $597M

+0.4%

Q4 2025

Nov 4, 2025

EPS

$0.78

Est $0.69

+13.9%

Revenue

$598M

Est $590M

+1.3%

Q3 2025

Jul 28, 2025

EPS

$0.75

Est $0.65

+15.4%

Revenue

$568M

Est $595M

-4.5%

Q2 2025

May 13, 2025

EPS

$0.62

Est $0.36

+73.1%

Revenue

$555M

Est $500M

+11.2%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q1 2026Latest	Feb 10, 2026	$0.94vs $0.77+22.1%	$599Mvs $597M+0.4%
Q4 2025	Nov 4, 2025	$0.78vs $0.69+13.9%	$598Mvs $590M+1.3%
Q3 2025	Jul 28, 2025	$0.75vs $0.65+15.4%	$568Mvs $595M-4.5%
Q2 2025	May 13, 2025	$0.62vs $0.36+73.1%	$555Mvs $500M+11.2%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	FCF Yield	Debt / Equity
INCYIncyte CorporationDirect Competitor	19.47B	97.47	15.21	21.22%	26.71%	29.31%	6.96%	0.01
ALKSAlkermes plcDirect Competitor	6.12B	36.25	25.35	-5.25%	16.37%	14.45%	7.85%	0.04
JAZZJazz Pharmaceuticals plcDirect Competitor	13.32B	212.26	-36.35	4.88%	0.66%	0.71%	9.74%	1.26
IONSIonis Pharmaceuticals, Inc.Direct Competitor	12.44B	75.25	-31.62	33.87%	-30.87%	-58.57%		5.35
HALOHalozyme Therapeutics, Inc.Direct Competitor	7.76B	65.87	25.73	37.55%	22.69%	6.49%	8.31%
ACADACADIA Pharmaceuticals Inc.Direct Competitor	3.78B	22.35	16.43	31.85%	24.94%	28.47%	4.16%	0.07
MRKMerck & Co., Inc.Product Competitor	279.49B	113.16	15.54	1.18%	28.12%	36.14%	4.42%	0.96
BMYBristol-Myers Squibb CompanyProduct Competitor	116.22B	56.92	16.50	-0.22%	15.01%	38.96%	11.05%	2.55

Compare EXEL vs Peers

Exelixis, Inc. (EXEL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs INCY

Most directly comparable listed peer for EXEL.

Scale Benchmark

vs MRK

Larger-name benchmark to compare EXEL against a more recognizable public peer.

Peer Set

Compare Top 5

vs INCY, ALKS, JAZZ, IONS

EXEL Income Statement

Exelixis, Inc. (EXEL) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Jan'25	Jan'26	TTM
Sales/Revenue	452.48M	853.83M	967.77M	987.54M	1.43B	1.61B	1.83B	2.17B	2.32B	2.38B
Revenue Growth %	136.34%	88.7%	13.35%	2.04%	45.31%	12.27%	13.6%	18.49%	6.98%	3.33%
Cost of Goods Sold	15.07M	26.35M	33.1M	36.27M	52.87M	57.91M	72.55M	76.22M	83.7M	64.53M
COGS % of Revenue	3.33%	3.09%	3.42%	3.67%	3.68%	3.59%	3.96%	3.51%	3.61%	-
Gross Profit	437.41M▲ 0%	827.48M▲ 89.2%	934.68M▲ 13.0%	951.27M▲ 1.8%	1.38B▲ 45.3%	1.55B▲ 12.4%	1.76B▲ 13.2%	2.09B▲ 19.0%	2.24B▲ 6.9%	1.7B▲ 0%
Gross Margin %	96.67%	96.91%	96.58%	96.33%	96.32%	96.41%	96.04%	96.49%	96.39%	71.57%
Gross Profit Growth %	136.56%	89.18%	12.96%	1.77%	45.29%	12.38%	13.17%	19.05%	6.88%	-
Operating Expenses	271.53M	388.62M	565.21M	841.21M	1.1B	1.35B	1.59B	1.49B	1.36B	1.37B
OpEx % of Revenue	60.01%	45.52%	58.4%	85.18%	76.34%	83.9%	86.7%	68.61%	58.8%	-
Selling, General & Admin	159.33M	206.37M	228.24M	293.36M	401.71M	459.86M	542.71M	492.13M	518.73M	521.15M
SG&A % of Revenue	35.21%	24.17%	23.58%	29.71%	27.99%	28.54%	29.65%	22.69%	22.36%	-
Research & Development	112.17M	182.26M	336.96M	547.85M	693.72M	891.81M	1.04B	910.41M	825M	599.44M
R&D % of Revenue	24.79%	21.35%	34.82%	55.48%	48.34%	55.36%	57.05%	41.98%	35.56%	-
Other Operating Expenses	0	397K	680K	912K	-184K	-197K	0	85.33M	20.51M	3M
Operating Income	165.91M▲ 0%	438.86M▲ 164.5%	369.47M▼ 15.8%	110.06M▼ 70.2%	286.67M▲ 160.5%	201.48M▼ 29.7%	170.88M▼ 15.2%	604.62M▲ 253.8%	872.19M▲ 44.3%	936.67M▲ 0%
Operating Margin %	36.67%	51.4%	38.18%	11.14%	19.98%	12.51%	9.34%	27.88%	37.59%	39.43%
Operating Income Growth %	689.92%	164.51%	-15.81%	-70.21%	160.46%	-29.71%	-15.19%	253.82%	44.26%	-
EBITDA	167.1M	443.77M	380.64M	119.2M	300.3M	222.36M	196.6M	633.42M	901.25M	958.38M
EBITDA Margin %	36.93%	51.97%	39.33%	12.07%	20.93%	13.8%	10.74%	29.21%	38.84%	40.34%
EBITDA Growth %	716.09%	165.58%	-14.23%	-68.68%	151.92%	-25.95%	-11.58%	222.18%	42.28%	21.04%
D&A (Non-Cash Add-back)	1.19M	4.92M	11.17M	9.14M	13.63M	20.88M	25.72M	28.8M	29.05M	21.71M
EBIT	167.11M	438.86M	398.11M	110.06M	286.67M	201.48M	170.88M	689.95M	892.7M	718.74M
Net Interest Income	-3.8M	12.84M	27.96M	19.86M	7.67M	33.06M	86.54M	77.16M	69.21M	50.14M
Interest Income	4.88M	12.84M	27.96M	19.86M	7.67M	33.06M	86.54M	77.16M	69.21M	66.26M
Interest Expense	8.68M	0	0	0	0	0	0	0	0	0
Other Income/Expense	-7.33M	13.24M	28.64M	20.78M	7.49M	32.87M	86.64M	77.02M	69.02M	50.18M
Pretax Income	158.58M▲ 0%	452.09M▲ 185.1%	398.11M▼ 11.9%	130.84M▼ 67.1%	294.15M▲ 124.8%	234.35M▼ 20.3%	257.52M▲ 9.9%	681.64M▲ 164.7%	941.21M▲ 38.1%	1B▲ 0%
Pretax Margin %	35.05%	52.95%	41.14%	13.25%	20.5%	14.55%	14.07%	31.43%	40.57%	42.23%
Income Tax	4.35M	-237.98M	77.1M	19.06M	63.09M	52.07M	49.76M	160.37M	158.64M	169.78M
Effective Tax Rate %	2.74%	-52.64%	19.37%	14.56%	21.45%	22.22%	19.32%	23.53%	16.85%	16.92%
Net Income	154.23M▲ 0%	690.07M▲ 347.4%	321.01M▼ 53.5%	111.78M▼ 65.2%	231.06M▲ 106.7%	182.28M▼ 21.1%	207.76M▲ 14.0%	521.27M▲ 150.9%	782.57M▲ 50.1%	833.42M▲ 0%
Net Margin %	34.09%	80.82%	33.17%	11.32%	16.1%	11.31%	11.35%	24.04%	33.73%	35.08%
Net Income Growth %	319.63%	347.44%	-53.48%	-65.18%	106.71%	-21.11%	13.98%	150.89%	50.13%	29.5%
Net Income (Continuing)	154.23M	690.07M	321.01M	111.78M	231.06M	182.28M	207.76M	521.27M	782.57M	833.42M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)	0.49▲ 0%	2.21▲ 351.0%	1.02▼ 53.8%	0.35▼ 65.7%	0.72▲ 105.7%	0.56▼ 22.2%	0.65▲ 16.1%	1.76▲ 170.8%	2.78▲ 58.0%	3.12▲ 0%
EPS Growth %	275%	351.02%	-53.85%	-65.69%	105.71%	-22.22%	16.07%	170.77%	57.95%	37.9%
EPS (Basic)	0.52	2.32	1.06	0.36	0.73	0.57	0.65	1.80	2.88	-
Diluted Shares Outstanding	312M	312.8M	315.01M	318M	322.36M	324.56M	321.46M	296.13M	281.86M	267.32M
Basic Shares Outstanding	293.59M	297.89M	302.58M	308.27M	314.88M	321.53M	318.15M	290.03M	271.57M	258.33M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

EXEL Balance Sheet

Exelixis, Inc. (EXEL) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Jan'25	Jan'26	TTM
Total Current Assets	484.87M	897.02M	1.01B	1.45B	1.83B	1.62B	1.32B	1.47B	1.44B	1.21B
Cash & Short-Term Investments	387.77M	693.33M	852.24M	1.21B	1.47B	1.31B	995.3M	1.11B	1.06B	777.21M
Cash Only	183.16M	314.77M	266.5M	319.22M	647.17M	501.19M	262.99M	217.37M	482.49M	226.15M
Short-Term Investments	204.61M	378.56M	585.74M	887.32M	819.9M	807.27M	732.31M	893.9M	576.6M	551.05M
Accounts Receivable	81.19M	162.77M	119.07M	160.88M	282.65M	214.78M	237.41M	265.44M	286.92M	328.95M
Days Sales Outstanding	65.5	69.58	44.91	59.46	71.9	48.66	47.35	44.67	45.14	46.78
Inventory	6.66M	9.84M	12.89M	20.97M	27.49M	33.3M	17.32M	22.39M	21.69M	26.61M
Days Inventory Outstanding	161.28	136.29	142.11	211.05	189.79	209.88	87.16	107.22	94.57	140.25
Other Current Assets	504K	0	0	0	0	62.21M	67.93M	68.48M	75.6M	75.88M
Total Non-Current Assets	170.42M	525.27M	874.48M	691.94M	781.49M	1.45B	1.62B	1.48B	1.4B	1.38B
Property, Plant & Equipment	25.74M	56.76M	90.73M	67.38M	104.03M	345.44M	470.85M	359.11M	441.26M	378.4M
Fixed Asset Turnover	17.58x	15.04x	10.67x	14.66x	13.79x	4.66x	3.89x	6.04x	5.26x	6.71x
Goodwill	63.68M	63.68M	63.68M	63.68M	63.68M	63.68M	63.68M	63.68M	63.68M	63.68M
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	64.25M	157.19M	536.38M	332.31M	371.11M	756.73M	728.72M	637.29M	603.6M	1.78B
Other Non-Current Assets	16.74M	3.52M	11.31M	71.85M	131M	55.77M	0	0	0	794.8M
Total Assets	655.29M▲ 0%	1.42B▲ 117.0%	1.89B▲ 32.6%	2.14B▲ 13.3%	2.62B▲ 22.4%	3.07B▲ 17.4%	2.94B▼ 4.2%	2.95B▲ 0.2%	2.84B▼ 3.5%	2.59B▲ 0%
Asset Turnover	0.69x	0.60x	0.51x	0.46x	0.55x	0.52x	0.62x	0.74x	0.82x	0.87x
Asset Growth %	9.67%	117.05%	32.58%	13.35%	22.41%	17.4%	-4.2%	0.18%	-3.5%	-20.14%
Total Current Liabilities	115.17M	105.47M	142.75M	204.66M	337.59M	324.36M	394.28M	403.77M	405.64M	370.98M
Accounts Payable	9.57M	10.9M	11.58M	23.63M	24.26M	32.67M	33.77M	38.19M	29.62M	24.15M
Days Payables Outstanding	231.97	151.01	127.72	237.81	167.46	205.9	169.89	182.9	129.19	148.41
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	31.98M	15.9M	6.6M	1.79M	7.81M	7.49M	0	0	0	0
Other Current Liabilities	52.54M	3.19M	15.13M	42.66M	45.55M	71.44M	82.12M	267.22M	287.5M	370.98M
Current Ratio	4.21x	8.50x	7.08x	7.06x	5.43x	4.99x	3.34x	3.63x	3.56x	3.56x
Quick Ratio	4.15x	8.41x	6.99x	6.96x	5.35x	4.89x	3.30x	3.58x	3.50x	3.50x
Cash Conversion Cycle	-5.2	54.86	59.3	32.7	94.23	52.64	-35.39	-31.01	10.52	38.63
Total Non-Current Liabilities	255.16M	29.36M	56.95M	53.56M	68.03M	258.7M	284.17M	299.72M	277.46M	286.87M
Long-Term Debt	0	0	0	0	0	0	0	0	0	169.54M
Capital Lease Obligations	14.53M	12.18M	48.01M	49.09M	51.27M	190.17M	189.94M	190.82M	173.04M	529.34M
Deferred Tax Liabilities	-14.53M	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	16.64M	1.29M	2.35M	721K	8.02M	61.95M	94.22M	108.89M	104.42M	462.95M
Total Liabilities	370.33M	134.83M	199.7M	258.22M	405.62M	583.06M	678.45M	703.49M	683.1M	657.85M
Total Debt	14.53M	14.92M	50.74M	49.09M	51.27M	190.17M	189.94M	190.82M	173.04M	169.54M
Net Debt	-168.63M	-299.86M	-215.76M	-270.13M	-595.9M	-311.02M	-73.05M	-26.55M	-309.45M	-56.61M
Debt / Equity	0.05x	0.01x	0.03x	0.03x	0.02x	0.08x	0.08x	0.09x	0.08x	0.08x
Debt / EBITDA	0.09x	0.03x	0.13x	0.41x	0.17x	0.86x	0.97x	0.30x	0.19x	0.18x
Net Debt / EBITDA	-1.01x	-0.68x	-0.57x	-2.27x	-1.98x	-1.40x	-0.37x	-0.04x	-0.34x	-0.34x
Interest Coverage	19.25x	-	-	-	-	-	-	-	-	-
Total Equity	284.96M▲ 0%	1.29B▲ 351.8%	1.69B▲ 31.0%	1.88B▲ 11.5%	2.21B▲ 17.6%	2.49B▲ 12.6%	2.26B▼ 9.0%	2.24B▼ 0.9%	2.16B▼ 3.7%	1.94B▲ 0%
Equity Growth %	219.04%	351.8%	30.95%	11.46%	17.64%	12.57%	-9.02%	-0.87%	-3.69%	-21.96%
Book Value per Share	0.91	4.12	5.35	5.91	6.86	7.67	7.04	7.58	7.67	7.24
Total Shareholders' Equity	284.96M	1.29B	1.69B	1.88B	2.21B	2.49B	2.26B	2.24B	2.16B	1.94B
Common Stock	296K	300K	305K	312K	319K	324K	303K	282K	262K	254K
Retained Earnings	-1.83B	-880.36M	-559.35M	-447.57M	-216.51M	-34.23M	-173.35M	-98.65M	-76.83M	-215.79M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-347K	-701K	3.07M	4.48M	-758K	-14.52M	-3.75M	-1.35M	3.48M	-415K
Minority Interest	0	0	0	0	0	0	0	0	0	0

EXEL Cash Flow Statement

Exelixis, Inc. (EXEL) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Jan'25	Jan'26	TTM
Cash from Operations	165.61M	415.72M	526.96M	208.98M	400.8M	362.61M	333.32M	699.97M	884.27M	884.27M
Operating CF Margin %	36.6%	48.69%	54.45%	21.16%	27.93%	22.51%	18.21%	32.28%	38.11%	-
Operating CF Growth %	-19.72%	151.02%	26.76%	-60.34%	91.79%	-9.53%	-8.08%	110%	26.33%	5.9%
Net Income	154.23M	690.07M	321.01M	111.78M	231.06M	182.28M	207.76M	521.27M	782.57M	833.42M
Depreciation & Amortization	1.19M	7.77M	8.35M	9.14M	13.63M	20.88M	25.72M	28.8M	29.05M	28.66M
Stock-Based Compensation	23.94M	44.32M	56.6M	105.07M	119.82M	107.57M	106.34M	93.84M	112.98M	116.1M
Deferred Taxes	3.26M	-244.11M	71M	15.27M	46.53M	-60.36M	-133.21M	-59.46M	126.24M	0
Other Non-Cash Items	-10.05M	-2.57M	2.91M	7.87M	28.77M	125.04M	140.68M	128.98M	24.62M	154.93M
Working Capital Changes	-6.95M	-79.76M	67.08M	-40.14M	-39.01M	-12.8M	-13.97M	-13.45M	-191.2M	-208.43M
Change in Receivables	-40.84M	-85.47M	43.72M	-42.47M	-122.32M	66.85M	-22.62M	-27.95M	-21.4M	-47.31M
Change in Inventory	-3.32M	-3.18M	-5.73M	-21.9M	-13.21M	-11.68M	-12.98M	5.45M	12.22M	8.91M
Change in Payables	3.01M	856K	39.69M	50.51M	55.09M	23.36M	53.25M	-21.89M	-50.15M	-76.55M
Cash from Investing	35.8M	-297.85M	-587.25M	-131.22M	-42.88M	-524.41M	-26.95M	-116.78M	350.44M	249.61M
Capital Expenditures	-21.14M	-33.3M	-12.83M	-30.34M	-54.23M	-27.71M	-40.47M	-28.43M	0	-2.64M
CapEx % of Revenue	4.67%	3.9%	1.33%	3.07%	3.78%	1.72%	2.21%	1.31%	1.72%	-
Acquisitions	164K	308K	0	0	0	0	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-1M	308K	0	0	-10M	-110.75M	-122.5M	-37.75M	-61.75M	-16.87M
Cash from Financing	-169.93M	9.69M	12.55M	-25.13M	-14.8M	586K	-546.05M	-628.81M	-969.59M	-1.13B
Debt Issued (Net)	-185.79M	-13K	0	0	0	0	0	0	0	0
Equity Issued (Net)	0	0	0	0	0	0	-550.38M	-652.03M	-898.37M	-626.07M
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-6.56M	-7.57M	0	0	0	0	-550.38M	-652.03M	-947.51M	-1.09B
Other Financing	15.86M	9.7M	12.55M	-25.13M	-14.8M	586K	4.33M	23.23M	-71.22M	-505.81M
Net Change in Cash	31.48M▲ 0%	127.56M▲ 305.2%	-47.74M▼ 137.4%	52.63M▲ 210.3%	343.12M▲ 551.9%	-161.21M▼ 147.0%	-239.68M▼ 48.7%	-45.62M▲ 81.0%	265.11M▲ 681.1%	256K▲ 0%
Free Cash Flow	144.47M▲ 0%	382.42M▲ 164.7%	514.12M▲ 34.4%	178.64M▼ 65.3%	336.58M▲ 88.4%	224.16M▼ 33.4%	170.35M▼ 24.0%	633.79M▲ 272.0%	844.34M▲ 33.2%	918.45M▲ 0%
FCF Margin %	31.93%	44.79%	53.12%	18.09%	23.46%	13.91%	9.31%	29.22%	36.39%	38.66%
FCF Growth %	-29.39%	164.71%	34.44%	-65.25%	88.42%	-33.4%	-24%	272.04%	33.22%	18.95%
FCF per Share	0.46	1.22	1.63	0.56	1.04	0.69	0.53	2.14	3.00	3.00
FCF Conversion (FCF/Net Income)	1.07x	0.60x	1.64x	1.87x	1.73x	1.99x	1.60x	1.34x	1.13x	1.10x
Interest Paid	20.46M	0	0	0	0	0	0	0	0	0
Taxes Paid	538K	10.68M	7.87M	4.12M	12.96M	127.87M	185.66M	170.48M	155.3M	0

EXEL Key Ratios

Exelixis, Inc. (EXEL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	82.41%	87.77%	21.59%	6.27%	11.3%	7.76%	8.74%	23.13%	35.53%	40.21%
Return on Invested Capital (ROIC)	102.38%	59.63%	22.55%	5.36%	13.34%	7.97%	5.87%	20.57%	32.15%	32.15%
Gross Margin	96.67%	96.91%	96.58%	96.33%	96.32%	96.41%	96.04%	96.49%	96.39%	71.57%
Net Margin	34.09%	80.82%	33.17%	11.32%	16.1%	11.31%	11.35%	24.04%	33.73%	35.08%
Debt / Equity	0.05x	0.01x	0.03x	0.03x	0.02x	0.08x	0.08x	0.09x	0.08x	0.08x
Interest Coverage	19.25x	-	-	-	-	-	-	-	-	-
FCF Conversion	1.07x	0.60x	1.64x	1.87x	1.73x	1.99x	1.60x	1.34x	1.13x	1.10x
Revenue Growth	136.34%	88.7%	13.35%	2.04%	45.31%	12.27%	13.6%	18.49%	6.98%	3.33%

EXEL SEC Filings & Documents

Exelixis, Inc. (EXEL) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 5, 2026·SEC

Material company update

Feb 10, 2026·SEC

Material company update

Jan 12, 2026·SEC

10-K Annual Reports

FY 2026

Feb 10, 2026·SEC

FY 2025

Feb 11, 2025·SEC

FY 2024

Feb 6, 2024·SEC

10-Q Quarterly Reports

FY 2026

May 5, 2026·SEC

FY 2025

Nov 4, 2025·SEC

FY 2025

Jul 28, 2025·SEC

EXEL Frequently Asked Questions

Exelixis, Inc. (EXEL) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Exelixis, Inc. (EXEL) reported $2.38B in revenue for fiscal year 2025. This represents a 22524% increase from $10.5M in 1999.

Exelixis, Inc. (EXEL) grew revenue by 7.0% over the past year. This is steady growth.

Yes, Exelixis, Inc. (EXEL) is profitable, generating $833.4M in net income for fiscal year 2025 (33.7% net margin).

Dividend & Returns

Exelixis, Inc. (EXEL) has a return on equity (ROE) of 35.5%. This is excellent, indicating efficient use of shareholder capital.

Exelixis, Inc. (EXEL) generated $918.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More EXEL

Exelixis, Inc. (EXEL) financial analysis — history, returns, DCA and operating performance tools

Full EXEL Stock Analysis

Analyst verdict, bull/bear case, risk factors and peer comparison

→

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Exelixis, Inc.(EXEL)Earnings, Financials & Key Ratios

EXEL Key Insights

✓Strengths

✗Weaknesses

EXEL Price & Volume

EXEL Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

EXEL Recent Earnings

EXEL Peer Comparison

Compare EXEL vs Peers

vs INCY

vs MRK

Compare Top 5

EXEL Income Statement

EXEL Balance Sheet

EXEL Cash Flow Statement

EXEL Key Ratios

EXEL SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

EXEL Frequently Asked Questions

Explore More EXEL

Full EXEL Stock Analysis

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation